Top-Rated Stocks NASDAQ:RCKT Rocket Pharmaceuticals - RCKT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $16.67 -0.33 (-1.94%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$16.23▼$17.1950-Day Range$16.67▼$22.6052-Week Range$7.57▼$23.48Volume977,290 shsAverage Volume1.06 million shsMarket Capitalization$1.32 billionP/E RatioN/ADividend YieldN/APrice Target$52.58 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Rocket Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside215.4% Upside$52.58 Price TargetShort InterestBearish10.47% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.18Based on 16 Articles This WeekInsider TradingSelling Shares$300,214 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.25) to ($2.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.69 out of 5 starsMedical Sector76th out of 1,005 stocksPharmaceutical Preparations Industry27th out of 486 stocks 4.5 Analyst's Opinion Consensus RatingRocket Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.58, Rocket Pharmaceuticals has a forecasted upside of 215.4% from its current price of $16.67.Amount of Analyst CoverageRocket Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.47% of the outstanding shares of Rocket Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRocket Pharmaceuticals has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Rocket Pharmaceuticals has recently increased by 9.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRocket Pharmaceuticals does not currently pay a dividend.Dividend GrowthRocket Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRocket Pharmaceuticals has received a 74.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Rocket Pharmaceuticals is -0.81. Previous Next 2.3 News and Social Media Coverage News SentimentRocket Pharmaceuticals has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Rocket Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 38 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.MarketBeat Follows14 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 56% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $300,214.00 in company stock.Percentage Held by Insiders33.67% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.23% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($3.25) to ($2.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rocket Pharmaceuticals is -5.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rocket Pharmaceuticals is -5.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRocket Pharmaceuticals has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Rocket Pharmaceuticals (NASDAQ:RCKT) StockRocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.Read More Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RCKT Stock News HeadlinesMarch 25, 2023 | msn.comRocket Lab reveals big supplier deal with mystery mega constellation customerMarch 24, 2023 | msn.comRocket Lab lifts off with 2 satellites onboard after unexpected solar storm delays launchMarch 26, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 23, 2023 | msn.comDestiny 2: How to Grapple onto Your RocketMarch 23, 2023 | nytimes.comRelativity Space Launches First 3-D Printed RocketMarch 23, 2023 | usnews.comRelativity's Debut Rocket Launch Proves Durability, Fails in SpaceMarch 23, 2023 | americanbankingnews.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $52.58 Average Target Price from BrokeragesMarch 22, 2023 | msn.comSir Elton John left stunned as he learns true inspiration behind Rocket ManMarch 26, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastMarch 21, 2023 | msn.comWatch Rocket Lab launch 2 satellites, recover booster early on March 22March 21, 2023 | forbes.comRocket League’s Hottest Battlecar Is In The Item Shop For A Limited TimeMarch 20, 2023 | msn.comWith Team Rocket retired, are these the Pokémon anime’s new villains?March 19, 2023 | nasdaq.comRocket Pharmaceuticals (RCKT) Shares Cross Below 200 DMAMarch 19, 2023 | msn.comRocket League: 10 Best Toppers, RankedMarch 17, 2023 | msn.comRocket Lab launches two radar imaging satellites from Virgina's Eastern ShoreMarch 17, 2023 | americanbankingnews.comEquities Analysts Set Expectations for Rocket Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:RCKT)March 17, 2023 | bizjournals.comRocket Lab plans rescheduled Virginia launch for ThursdayMarch 16, 2023 | msn.comSiddharth Roy Kapur, Nikkhil Advani Talk SonyLIV’s ‘Rocket Boys’ Season 2March 16, 2023 | americanbankingnews.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) to Post Q1 2023 Earnings of ($0.83) Per Share, SVB Leerink ForecastsMarch 14, 2023 | msn.comPokémon’s Team Rocket blasts off for what may be the final timeMarch 13, 2023 | forbes.comRocket Launch Visible To 100 Million Will Look Like A Speeding StarMarch 1, 2023 | finance.yahoo.comRocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care ConferenceMarch 1, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About Rocket PharmaceuticalsMarch 1, 2023 | finance.yahoo.comWhat Makes Rocket Pharmaceuticals (RCKT) Shares Attractive?February 27, 2023 | msn.comRocket Pharmaceuticals GAAP EPS of -$0.92 misses by $0.10February 27, 2023 | finance.yahoo.comRocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational ResultsFebruary 23, 2023 | bizjournals.comRapid delivery startup Food Rocket leaves San Francisco for CharlotteSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RCKT Company Calendar Last Earnings2/27/2023Today3/25/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RCKT CUSIPN/A CIK1281895 Webwww.rocketpharma.com Phone(609) 659-8001Fax646-224-9585Employees151Year Founded2018Price Target and Rating Average Stock Price Forecast$52.58 High Stock Price Forecast$75.00 Low Stock Price Forecast$34.00 Forecasted Upside/Downside+215.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-221,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.39% Return on Assets-47.69% Debt Debt-to-Equity Ratio0.04 Current Ratio9.29 Quick Ratio9.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.47 per share Price / Book2.58Miscellaneous Outstanding Shares79,350,000Free Float52,632,000Market Cap$1.32 billion OptionableOptionable Beta1.23 Social Links Key ExecutivesGaurav D. ShahChief Executive Officer & DirectorKinnari PatelPresident & Chief Operating OfficerJohn C. MilitelloTreasurer, Chief Financial & Accounting OfficerJonathan David SchwartzChief Medical Officer & SVP-Clinical DevelopmentMayo PujolsChief Technical Officer & Executive Vice PresidentKey CompetitorsAvidity BiosciencesNASDAQ:RNAChinook TherapeuticsNASDAQ:KDNYCureVacNASDAQ:CVACCinCor PharmaNASDAQ:CINCTravere TherapeuticsNASDAQ:TVTXView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCBought 5,211 shares on 3/23/2023Ownership: 0.036%Rockefeller Capital Management L.P.Bought 5,000 shares on 3/6/2023Ownership: 0.059%Voya Investment Management LLCSold 10,088 shares on 2/28/2023Ownership: 0.040%Gaurav ShahSold 12,194 sharesTotal: $232,417.64 ($19.06/share)Jonathan David SchwartzSold 3,557 sharesTotal: $67,796.42 ($19.06/share)View All Insider TransactionsView All Institutional Transactions RCKT Stock - Frequently Asked Questions Should I buy or sell Rocket Pharmaceuticals stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCKT shares. View RCKT analyst ratings or view top-rated stocks. What is Rocket Pharmaceuticals' stock price forecast for 2023? 12 equities research analysts have issued 1 year price targets for Rocket Pharmaceuticals' stock. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they expect the company's stock price to reach $52.58 in the next twelve months. This suggests a possible upside of 215.4% from the stock's current price. View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts. How have RCKT shares performed in 2023? Rocket Pharmaceuticals' stock was trading at $19.57 at the beginning of 2023. Since then, RCKT shares have decreased by 14.8% and is now trading at $16.67. View the best growth stocks for 2023 here. When is Rocket Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our RCKT earnings forecast. How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its earnings results on Monday, February, 27th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by $0.10. During the same quarter in the previous year, the firm earned ($0.69) earnings per share. What ETFs hold Rocket Pharmaceuticals' stock? ETFs with the largest weight of Rocket Pharmaceuticals (NASDAQ:RCKT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Global X Guru Index ETF (GURU), Harbor Health Care ETF (MEDI), ALPS Medical Breakthroughs ETF (SBIO), Harbor Disruptive Innovation ETF (INNO), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA). What is Rocket Pharmaceuticals' stock symbol? Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT." Who are Rocket Pharmaceuticals' major shareholders? Rocket Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Maverick Capital Ltd. (4.49%), RA Capital Management L.P. (3.18%), Price T Rowe Associates Inc. MD (2.49%), Avidity Partners Management LP (2.02%), Dimensional Fund Advisors LP (1.49%) and Geode Capital Management LLC (1.46%). Insiders that own company stock include Gaurav Shah, Gotham Makker, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp. View institutional ownership trends. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Rocket Pharmaceuticals' stock price today? One share of RCKT stock can currently be purchased for approximately $16.67. How much money does Rocket Pharmaceuticals make? Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.32 billion. The biotechnology company earns $-221,860,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis. How many employees does Rocket Pharmaceuticals have? The company employs 151 workers across the globe. How can I contact Rocket Pharmaceuticals? Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (609) 659-8001, via email at investors@rocketpharma.com, or via fax at 646-224-9585. This page (NASDAQ:RCKT) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.